$BDSX

BIODESIX INC

Biodesix provides diagnostic testing services for healthcare providers treating patients with lung disease, as well as testing and consulting services for biopharmaceutical, life sciences and diagnostic companies. It uses genomics, proteomics, radiomics and artificial intelligence to develop and commercialize diagnostic tests. Its two business segments are Lung Diagnostic Testing and Development Services. The lung testing portfolio includes five blood-based tests: Nodify CDT and Nodify XL2 assess cancer risk in lung nodules, while VeriStrat, GeneStrat ddPCR and GeneStrat NGS support treatment guidance for non-small cell lung cancer. Development Services offers translational research, biomarker discovery, assay design, test development and validation, clinical-trial testing, and regulatory, reimbursement, commercialization and logistics support. Biodesix earns money by providing lung diagnostic testing to healthcare providers and diagnostic testing and consulting services to its industry and academic customers. It is headquartered in Louisville, Colorado.

0
1
0
$1.0M
—
SCHULER JACK W
0%
See all $BDSX insider activity →
Low

New Methylation Profiling Assay for Liquid Biopsy

mDETECT and Thermo Fisher Scientific launched a research assay for cancer detection via methylation profiling of circulating tumor DNA (ctDNA) in blood samples. The Ion AmpliSeq HD Lung Cancer cfDNA Methylation Assay combines mDETECT's methylation analysis with Thermo Fisher's Ion AmpliSeq HD technology. Biodesix will evaluate the assay for lung cancer diagnostics. The assay is for research use only, not yet for diagnostics.

BDSX sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 1 news story mentioning BDSX (BIODESIX INC). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.

Recent BDSX coverage spans earnings, technology and financial news.

In the last 30 days, BDSX insiders filed 1 SEC Form 4 transaction — 1 purchase ($1.0M) and no sales. The most active reporter was SCHULER JACK W with 1 filing.

What's driving BDSX

AlphAI scores every news story that mentions BDSX with an AI model for sentiment and relevance, and aggregates insider trades from BIODESIX INC's SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $BDSX

Score

New Methylation Profiling Assay for Liquid Biopsy

mDETECT and Thermo Fisher Scientific launched a research assay for cancer detection via methylation profiling of circulating tumor DNA (ctDNA) in blood samples. The Ion AmpliSeq HD Lung Cancer cfDNA Methylation Assay combines mDETECT's methylation analysis with Thermo Fisher's Ion AmpliSeq HD technology. Biodesix will evaluate the assay for lung cancer diagnostics. The assay is for research use only, not yet for diagnostics.

Biodesix Q3FY26 Results: Revenue misses estimates, stock falls 29%

Biodesix Inc reported Q3FY26 revenue of $24.0M, missing estimates of $27.44M. Shares fell 29.44% after-hours. Full-year guidance was reduced to $101M-$103M from $108M-$114M. Revenue growth was 10% YoY, but test volume growth was offset by lower revenue per test. Gross margin remained at 81%, and net loss improved 8% YoY to $8.0M.

$BDSXLowExec change· resigned

BIODESIX INC (BDSX): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

BIODESIX INC (BDSX) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On November 2, 2026, it was agreed that the employment of Kieran O’Kane, Chief Commercial Officer of Biodesix, Inc. (the “

$BDSXMedEarnings

Biodesix Announces Third Quarter 2026 Results and Highlights

BIODESIX INC (BDSX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Biodesix Announces Third Quarter 2026 Results and Highlights Delivered total revenue of $24.0 million, an increase of 10% year over year Grew Diagnostic Testing revenue 16% year over year, with test volumes increasing 24% Maintained an 81% gross margin, improved Net

A new six-step lung nodule plan puts risk-assessment tests at its core

Biodesix, Inc. (BDSX) announced the American College of Chest Physicians (CHEST) published a new framework for lung nodule programs, featuring its Nodify Lung® tests. The six-step plan, developed by a multidisciplinary panel, emphasizes biomarker testing for risk assessment. Biodesix's CEO highlighted the validation of their tests in the framework, which was presented at the 2026 CHEST Annual Meeting.

Related tickers